SG11201901374WA - Antibiotic compounds - Google Patents
Antibiotic compoundsInfo
- Publication number
- SG11201901374WA SG11201901374WA SG11201901374WA SG11201901374WA SG11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA SG 11201901374W A SG11201901374W A SG 11201901374WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compounds
- merrifield
- lane
- centre
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614314.1A GB201614314D0 (en) | 2016-08-22 | 2016-08-22 | Antibiotic compounds |
| PCT/GB2017/052478 WO2018037223A1 (en) | 2016-08-22 | 2017-08-22 | Antibiotic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901374WA true SG11201901374WA (en) | 2019-03-28 |
Family
ID=57045563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901374WA SG11201901374WA (en) | 2016-08-22 | 2017-08-22 | Antibiotic compounds |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20190194179A1 (zh) |
| EP (1) | EP3500567A1 (zh) |
| JP (1) | JP2019528291A (zh) |
| KR (1) | KR20190046894A (zh) |
| CN (1) | CN109923111A (zh) |
| AU (1) | AU2017316742A1 (zh) |
| BR (1) | BR112019003427A2 (zh) |
| CA (1) | CA3034000A1 (zh) |
| CO (1) | CO2019002624A2 (zh) |
| EA (1) | EA201990551A1 (zh) |
| GB (1) | GB201614314D0 (zh) |
| MX (1) | MX2019001978A (zh) |
| PH (1) | PH12019500360A1 (zh) |
| SG (1) | SG11201901374WA (zh) |
| WO (1) | WO2018037223A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3636645A1 (de) | 2018-10-11 | 2020-04-15 | Bayer Aktiengesellschaft | Verfahren zur herstellung schwefel-substituierter pyridinderivate |
| CN112867713B (zh) | 2018-10-11 | 2023-05-05 | 拜耳公司 | 制备咪唑衍生物的方法 |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| EP3927711A4 (en) * | 2019-02-22 | 2022-11-16 | Anifera Limited | COMPOSITIONS PROVIDING ENHANCED ANTIBACTERIAL ACTIVITY AGAINST GRAM POSITIVE BACTERIA AND THEIR USE |
| CN111808093B (zh) * | 2019-04-12 | 2023-05-16 | 中国医学科学院医药生物技术研究所 | 一种新德里金属-β-内酰胺酶-1抑制剂 |
| BR112021020055A2 (pt) | 2019-04-12 | 2021-12-07 | Mitobridge Inc | Indutores de hmox1 |
| CN116528873A (zh) * | 2020-11-19 | 2023-08-01 | A&J科学有限公司 | 新型化合物、其制造方法及包含其的抗生素组合物 |
| CN113185475A (zh) * | 2021-04-29 | 2021-07-30 | 江苏永凯化学有限公司 | 一种高效低污染的精恶唑禾草灵生产工艺 |
| WO2023234970A1 (en) * | 2022-06-01 | 2023-12-07 | KUDA Therapeutics, Inc. | Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis |
| WO2024130173A1 (en) * | 2022-12-16 | 2024-06-20 | Immvention Therapeutix | Benzimidazole derivatives |
| CN117003710A (zh) * | 2023-07-19 | 2023-11-07 | 镇江先锋植保科技有限公司 | 一种2-巯基-6-氯苯并恶唑的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604217B2 (en) * | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| JP5786402B2 (ja) * | 2011-03-29 | 2015-09-30 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| WO2016039939A1 (en) * | 2014-09-09 | 2016-03-17 | Ptc Therapeutics, Inc. | Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds |
-
2016
- 2016-08-22 GB GBGB1614314.1A patent/GB201614314D0/en not_active Ceased
-
2017
- 2017-08-22 AU AU2017316742A patent/AU2017316742A1/en not_active Withdrawn
- 2017-08-22 CA CA3034000A patent/CA3034000A1/en not_active Abandoned
- 2017-08-22 SG SG11201901374WA patent/SG11201901374WA/en unknown
- 2017-08-22 BR BR112019003427-7A patent/BR112019003427A2/pt not_active Application Discontinuation
- 2017-08-22 CN CN201780063473.8A patent/CN109923111A/zh active Pending
- 2017-08-22 WO PCT/GB2017/052478 patent/WO2018037223A1/en unknown
- 2017-08-22 EA EA201990551A patent/EA201990551A1/ru unknown
- 2017-08-22 US US16/327,286 patent/US20190194179A1/en not_active Abandoned
- 2017-08-22 MX MX2019001978A patent/MX2019001978A/es unknown
- 2017-08-22 JP JP2019510688A patent/JP2019528291A/ja not_active Withdrawn
- 2017-08-22 KR KR1020197008269A patent/KR20190046894A/ko not_active Application Discontinuation
- 2017-08-22 EP EP17761308.0A patent/EP3500567A1/en not_active Withdrawn
-
2019
- 2019-02-20 PH PH12019500360A patent/PH12019500360A1/en unknown
- 2019-03-21 CO CONC2019/0002624A patent/CO2019002624A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019001978A (es) | 2019-08-01 |
| BR112019003427A2 (pt) | 2019-05-21 |
| CA3034000A1 (en) | 2018-03-01 |
| GB201614314D0 (en) | 2016-10-05 |
| CN109923111A (zh) | 2019-06-21 |
| CO2019002624A2 (es) | 2019-05-31 |
| PH12019500360A1 (en) | 2019-11-11 |
| KR20190046894A (ko) | 2019-05-07 |
| WO2018037223A1 (en) | 2018-03-01 |
| EA201990551A1 (ru) | 2019-12-30 |
| JP2019528291A (ja) | 2019-10-10 |
| AU2017316742A1 (en) | 2019-04-11 |
| US20190194179A1 (en) | 2019-06-27 |
| EP3500567A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11202000266VA (en) | Quinoline derivatives for treating infections with helminths | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201811221XA (en) | Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201811345TA (en) | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |